ATS 2019 Virtual Final Program

718 Obstructive Sleep Apnea Promotes Accumulation of Free Cholesterol in Endothelial Cells/ S. Gao, M. Emin, K. Pastellas, R. Shah, S. Jelic, New York, NY, p.A4466 719 Sleep and Neurodegeneration in a Mouse Model of Parkinson’s Disease/ T. Gallego Martin, B. Chuan, J. Callio, L. Guo, N. Obidike, F. Shah, M. Bueno, C.T. Chu, A.L. Mora, C.P. O’Donnell, Pittsburgh, PA, p.A4467 720 Fluid-Structure Interaction Simulations and Experiments of Airflow Limitation in Models of Obstructive Sleep Apnea/ G. Garcia, M.G. Moghaddam, T.B. Le, Milwaukee, WI, p.A4468 721 Foxp3 + Regulatory T Cells Were Overexpressed in PeripheralBlood of Patients with Non-Small Cell Lung Cancer and Obstructive Sleep Apnea/ Y. Liu, X. Gao, Guangzhou, China, p.A7392 CLINICAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION C30 LUNG CANCER SCREENING: LESSONS FROM THE FRONT-LINE 9:15 a.m. - 11:15 a.m. KBHCCD Arena (Level 2) Abstract Summaries 9:15-9:45 Viewing/Discussion 9:45-11:15 Chairing: P.J. Mazzone, MPH, MD, Cleveland, OH P. Sather, APRN,BC, New Haven, CT A.C. Melzer, MD, MS, Minneapolis, MN 401 Prevalence, Symptom Burden and Under-Diagnosis of COPD in a Lung Cancer Screening Cohort/ M. Ruparel, S.L. Quaife, J.L. Dickson, S. Tisi, H. Hall, C. Horst, M. Taylor, A. Ahmed, P. Shaw, S.J. Burke, M.-J. Soo, A. Nair, A. Devaraj, K. Sennett, S.W. Duffy, N. Navani, A. Bhowmik, D.R. Baldwin, S.M. Janes, London, United Kingdom, p.A4469 402 Clinical Significance of Infectious, Inflammatory and Structural Pulmonary Incidental Findings Identified on Initial Lung Cancer Screening Exams/ A.E. Fabbrini, A.C. Melzer, K.L. Rice, B. Clothier, A. Bangerter, T. Do, S. Fu, Minneapolis, MN, p.A4470 403 Occupational Risk, Race, and Lung Cancer Incidence in the National Lung Screening Trial/ J. Barta, M. Rojulpote, M. Lake, R. McIntire, H. Juon, Philadelphia, PA, p.A4471 404 Quantitative Body Composition is Associated with the Development of Lung Cancer in a Large Lung Cancer Screening Cohort/ L. Jarnagin, G. Rizzo, W. Thedinger, C. Stefanescu, W.P. Long, A. Sanayei, S. Regis, B.J. McKee, A. McKee, C. Wald, G.R. Washko, R. San Jose Estepar, L. Gazourian, Burlington, MA, p.A4472 405 Correlation of a Co-Morbidity Index with Time-to-Death from Baseline Lung Cancer Screening Computed Tomography in a Veteran Population/ A. Schiff, S. Greene, E.J. Gartman, M.D. Jankowich, L. Nici, Providence, RI, p.A4473 406 Prevalence and 12-Month Downstream Costs of Incidental Findings in a Single-Center Lung Cancer Screening Program/ M.S. Godfrey, P. Sather, L.T. Tanoue, M.A. Pisani, New Haven, CT, p.A4474 407 Lung Cancer Risk (PLCO m2012 ) and Surgical Rates for Lung Cancer in a Post-Hoc Analysis of the National Lung Screening Trial (NLST-ACRIN, N=10,054)/ R.J. Hopkins, F. Duan, C. Chiles, G. Gamble, G.A. Silvestri, R.P. Young, Auckland, New Zealand, p.A4475 408 Lung Cancer Risk (PLCO m2012 ) and Pre-Existing Respiratory Morbidity in a Post-Hoc Analysis of the National Lung Screening Trial (NLST-ACRIN, N=10,054)/ R.J. Hopkins, F. Duan, C. Chiles, G.D. Gamble, G.A. Silvestri, R.P. Young, Auckland, New Zealand, p.A4476 409 The Association Between Emphysematous Changes on Lung Cancer Screening Low-Dose CT Scans and Lung-RADS Scoring/ P. Kirupaharan, S. Vehar, R. Yadav, P.J. Mazzone, H. Choi, Cleveland, OH, p.A4477 410 Selection Criteria for Lung Cancer Screening in African Americans/ K. Spencer, H. Mengiste, R. Ogunti, P. Whitesell, C. Williams, Washington, DC, p.A4478 411 Changes in Perceptions and Practice in Lung Cancer Screening Among Primary Care Physicians in Kentucky/ S. Annangi, T. McCann, G. Du, J. Studts, D. Kristine, J. Alexander, E. Bensadoun, Lexington, KY, p.A4479 412 Genetic Susceptibility to Lung Cancer and COPD in the National Lung Screening Trial (NLST): COPD Masks AGER Gene Susceptibility to Lung Cancer/ R.P. Young, R.J. Hopkins, F. Duan, C. Chiles, D. Aberle, G.A. Silvestri, P. Billings, G. Gamble, Auckland, New Zealand, p.A4480 413 Computed Tomographic Calcium Scoring Scan Should Include the Upper Lung Fields to Screen for Lung Cancer: A Cost Effectiveness Analysis/ B. Jiang, P. Linden, S. Worrell, V. Ho, C. Towe, Cleveland, OH, p.A4481 414 The Challenge of Achieving Appropriate Follow-Up in a Community Lung Cancer Screening Program/ M.A. Bernstein, S. Gold, M. Ronk, L. Drysdale, J. Krinsley, M.I. Ebright, Stamford, CT, p.A4482 415 High Variability in Radiologist Reporting of Incidental Findings During Lung Cancer Screening in a Community-Based Healthcare Network/ S. Anton, L.C. Horslen, C. Henson, C.L. Wilshire, C.R. Gilbert, K.M. Spiegel, J.R. Rayburn, A.S. Carlson, C.C. Fuller, B.M. McCall, R.K. Weerasinghe, E. Vallieres, J.A. Gorden, Seattle, WA, p.A4483 416 Assessing the Optimal Management of Early Stage Lung Cancer in Veterans/ J.P. Wisnivesky, K. Sigel, S. Bates, K. Stone, J. Kong, New York, NY, p.A4484 417 The Influence of Patient Comorbidities on Clinician Approaches to Lung Cancer Screening: A Qualitative Analysis/ J. Iaccarino, E. Koppelman, R.S. Wiener, Boston, MA, p.A4485 418 Frequency, Significance, and Outcome of Incidental Findings Identified on Initial Lung Cancer Screening Exams/ A.C. Melzer, A.E. Fabbrini, K.L. Rice, B. Clothier, A. Bangerter, S.S. Fu, Minneapolis, MN, p.A4486 ATS 2019 • Dallas, TX TUESDAY • MAY 21 239 TUESDAY MORNING